Financial Perspectives’s Jazz Pharmaceuticals JAZZ Stock Holding History

Financial Perspectives’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-504	Closed	-$89.5K	–	655
2021 Q2	$89.5K	Buy	504 +6	+1%	+$1.04K	0.04%	197
2021 Q1	$81.9K	Hold	498	–	–	0.04%	192
2020 Q4	$82.2K	Hold	498	–	–	0.05%	184
2020 Q3	$71K	Hold	498	–	–	0.05%	171
2020 Q2	$54.9K	Hold	498	–	–	0.04%	182
2020 Q1	$49.7K	Hold	498	–	–	0.04%	165
2019 Q4	$74.3K	Buy	+498	New	+$67.8K	0.05%	145

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Financial Perspectives's JAZZ Position: Q3 2021 in Review

Financial Perspectives sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 504 shares — an estimated $89.5K sold.

Financial Perspectives first reported a position in JAZZ in Q4 2019 and held it in 7 quarters. The position peaked at $89.5K in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Financial Perspectives reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Financial Perspectives sold 504 Jazz Pharmaceuticals shares in Q3 2021, an estimated $89.5K.
Financial Perspectives first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Financial Perspectives's Jazz Pharmaceuticals position peaked at $89.5K in Q2 2021.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Financial Perspectives's 13F filing for Q3 2021, filed 10 Jan 2024.